Sensorion Stock

Sensorion EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Sensorion (ALSEN.PA) as of Jul 24, 2026 is -10.51. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -13.38 — a change of -21.44% (higher).

EV/EBIT

-10.51

YoY

-21.44%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Sensorion is 2026 -10.51 . EV/EBIT (Enterprise Value to EBIT) of Sensorion was 2025 -13.38 . It decreases by -21.44% higher compared to the previous year.

The Sensorion EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-1.46 base
Jan 1, 2020
-10.25 base
Jan 1, 2021
-10.22 base
Jan 1, 2022
-1.28 base
Jan 1, 2023
-2.57 base
Jan 1, 2024
-6.36 base
Jan 1, 2025 (e)
-2.54 base
Jan 1, 2026 (e)
-3.27 base
YEARPRICE-TO-EBIT
2026 est -3.27
2025 est -2.54
2024 -6.36
2023 -2.57
2022 -1.28
2021 -10.22
2020 -10.25
2019 -1.46
2018 -0.94
2017 -2.80
2016 -3.67
2015 -7.32
2014 -
2013 -
2012 -
Access this data via the Eulerpool API
Get Free API Key

Sensorion Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Sensorion's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Sensorion's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Sensorion's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Sensorion grows earnings faster than its peers.

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

EV/EBIT (Enterprise Value to EBIT) of Sensorion is -10.51 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Sensorion

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Sensorion